New combo therapy for tough breast cancer shows promise, but trial halted early
Disease control
Terminated
This study tested a combination of two drugs, ZEN003694 and talazoparib, in people with triple-negative breast cancer who do not have BRCA gene mutations. The goal was to see if the combination could shrink tumors or slow the disease. The trial was terminated early, so results ar…
Phase: PHASE2 • Sponsor: Zenith Epigenetics • Aim: Disease control
Last updated May 15, 2026 11:56 UTC